Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Gains from Sales and Divestitures of $21318.0 for Q1 2026, up 93.75% year-over-year from $11003.0 in Q1 2025, and up 9.3% quarter-over-quarter from $19505.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Gains from Sales and Divestitures data on file, last reported at $21318.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $21318.0, up 93.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $21318.0 (up 93.75% YoY), and the FY2025 annual result was $19505.0, down 12.64% from the prior year.
- Gains from Sales and Divestitures improved to $21318.0 in Q1 2026 per FULC's latest filing, from $19505.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $22326.0 in Q2 2024 and troughed at $5496.0 in Q1 2023.
- A 5-year average of $16212.1 and a median of $18144.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2024: Gains from Sales and Divestitures sank 76.26% in 2022, then soared 110.15% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $10174.0 in 2022, then soared by 78.34% to $18144.0 in 2023, then advanced by 23.05% to $22326.0 in 2024, then decreased by 12.64% to $19505.0 in 2025, then grew by 9.3% to $21318.0 in 2026.
- Business Quant data shows FULC's Gains from Sales and Divestitures at $21318.0 in Q1 2026, $19505.0 in Q4 2025, and $19505.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,318.00 |
| Mar 31, 2026 | 21,318.00 |
| Dec 31, 2025 | 19,505.00 |
| Dec 31, 2025 | 19,505.00 |
| Sep 30, 2025 | 19,505.00 |
| Sep 30, 2025 | 19,505.00 |
| Jun 30, 2025 | 19,505.00 |
| Jun 30, 2025 | 19,505.00 |
| Mar 31, 2025 | 11,003.00 |
| Mar 31, 2025 | 11,003.00 |
| Dec 31, 2024 | 22,326.00 |
| Dec 31, 2024 | 22,326.00 |
| Sep 30, 2024 | 22,326.00 |
| Sep 30, 2024 | 22,326.00 |
| Jun 30, 2024 | 22,326.00 |
| Jun 30, 2024 | 22,326.00 |
| Mar 31, 2024 | 11,550.00 |
| Mar 31, 2024 | 11,550.00 |
| Dec 31, 2023 | 18,144.00 |
| Dec 31, 2023 | 18,144.00 |